Martha M. Wadleigh

Martha M. Wadleigh

Oncology | Hematology

450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 09, 2026

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Journal: Haematologica

Published: November 10, 2025

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Journal: Blood neoplasia

Published: September 18, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances

Published: September 16, 2025

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Journal: Blood advances

Published: September 16, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances

Published: August 19, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances

Published: August 19, 2025

Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.

Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.

Journal: Haematologica

Published: August 07, 2025

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.

Journal: Blood cancer journal

Published: July 31, 2024

A Hospice Transitions Program for Patients in the Emergency Department.

A Hospice Transitions Program for Patients in the Emergency Department.

Journal: JAMA network open

Published: July 08, 2024

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.

Journal: Blood

Published: June 17, 2024

Showing 1-12 of 100

Last Updated: 09/26/2026